predictBBB.ai

Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]

Dallas Biotech Launches Open-Access AI Tool Targeting One of Brain Drug Discovery’s Toughest Hurdles

by | Aug 20, 2025
With just 2% to 6% of small-molecule drugs able to cross the blood-brain barrier, researchers and drugmakers face steep odds. Lantern Pharma’s tool, the company’s CEO says, could be “a paradigm shift” in developing treatments for conditions ranging from brain cancers to Parkinson’s disease.
MORE►
A Special Thank you to our sponsors

Dallas Innovates is owned by the Dallas Regional Chamber. Editorial operations are led independently by Lawley Head Media.

© Copyright 2026 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners